Clinical trial

Expanded Access to Veliparib

NCT03123211

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2022-05-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Soundunresolved

Triple Negative Breast Cancer (TNBC)unresolved

High Grade Serous Ovarian Cancerunresolved

Patients Requiring Veliparib Suspension Formulationunresolved

Interventions

VeliparibDRUG

Sponsors & collaborators

AbbVielead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03123211 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.